01:32 AM EDT, 07/21/2026 (MT Newswires) -- Bachem (BANB.SW) plans to invest over 500 million francs in a large-scale peptide production facility in Sisslerfeld, Eiken, Switzerland, under a strategic collaboration. The Swiss peptides and oligonucleotides manufacturing company said Tuesday the investment will follow an agreement to supply large volumes of peptides. Commercial production at the new site is expected to start in 2030.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.